Nonclinical Efficacy and Safety of CX-2029, an Anti-CD71 Probody–Drug ConjugateShweta Singh, Jennifer Richardson, Andrew Jang et al.|Molecular Cancer Therapeutics|2022Cited by 35
SAR and characterization of non-substrate isoindoline urea inhibitors of nicotinamide phosphoribosyltransferase (NAMPT)Michael L. Curtin, Michael R. Michaelides, H. Robin Heyman et al.|Bioorganic & Medicinal Chemistry Letters|2017Cited by 21
Abstract B116: Optimizing a CD71-targeting Probody drug conjugate (PDC) for activity in multiple solid tumor and lymphoma models and for tolerability in nonhuman primatesShweta Singh, Michael Kavanaugh, Laura Serwer et al.|Molecular Cancer Therapeutics|2018Cited by 5
Data from Nonclinical Efficacy and Safety of CX-2029, an Anti-CD71 Probody–Drug ConjugateShweta Singh, Jennifer Richardson, Laura Serwer et al.|Unknown|2023Cited by 0
Supplementary Data from Nonclinical Efficacy and Safety of CX-2029, an Anti-CD71 Probody–Drug ConjugateShweta Singh, Jennifer Richardson, Laura Serwer et al.|Unknown|2023Cited by 0